CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD)....
Phase 1
Berlin, Germany and 17 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Berlin, Germany and 319 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Berlin, Germany and 295 other locations
receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...
Phase 2
Berlin, Germany and 188 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Berlin, Germany and 145 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Berlin, Germany and 129 other locations
performed thus far excluded patients with an eGFR below 25 mL/min/1.73m2 at inclusion, prevalent dialysis patients, and kidney transplant r...
Phase 3
Berlin, Germany and 64 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Berlin, Germany and 744 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Berlin, Germany and 950 other locations
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This...
Phase 3
Berlin, Germany and 591 other locations
Clinical trials
Research sites
Resources
Legal